| Document |
Document Title |
|
WO/2024/067463A1 |
Provided are a compound of formula (I) or a pharmaceutically acceptable salt, ester, optical isomer, tautomer, stereoisomer, polymorph, solvate, N-oxide, isotope-labeled compound, metabolite, chelate, complex, inclusion compound or prodr...
|
|
WO/2024/062344A1 |
The present disclosure encompasses Mesdopetam salts, solid state forms of Mesdopetam and salts thereof, in embodiments processes for preparation thereof and pharmaceutical compositions thereof.
|
|
WO/2024/044813A1 |
The present invention relates to novel fluoroallylamine sulfone derivatives that are capable of inhibiting certain amine oxidase enzymes. These compounds are useful for the treatment of a variety of indications, e.g., fibrosis, cancer an...
|
|
WO/2024/042540A1 |
The present invention relates to a composition comprising Mesdopetam alone or in combination with proton pump inhibitor which can be administered either separately i.e. by co-administration or in a fixed dose combination (FDC) in the tre...
|
|
WO/2024/040235A1 |
Provided herein are compounds of formula (A): or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein X1, X2, X3, X4, Z1, Z2, Z3, Z4, Ra, Rb, Rc, Rd, Re, L, Y, and m are as defined he...
|
|
WO/2024/020101A1 |
Provided are compounds for inhibiting prostaglandin E synthase 3 (PTGES3) along with methods of treating prostate cancer by administering such compounds to a subject. The PTGES3 inhibitors has a moiety that can form a covalent bond with ...
|
|
WO/2024/007862A1 |
Provided are a para-substituted biphenyl thioether compound, a composition, and use thereof. The compound has a structure represented by formula (I): , the definitions of the groups in the formula are provided in the description. The par...
|
|
WO/2024/010782A1 |
Disclosed are compounds of Formula (I) or pharmaceutically acceptable salts or solvates thereof, wherein R1, R3, X, Y, Z, and W arc as defined herein. The compounds are, for example, inhibitors of WRN helicase and useful in treating a pr...
|
|
WO/2022/266394A9 |
The present disclosure provides a compound having the structure : Formula (I) or Formula (II).
|
|
WO/2024/002633A1 |
In a first aspect, the present invention provides a method for producing a compound of general formula (I) starting from methionine with an intermediate product of methionine sulfoxide. The method according to the present invention allow...
|
|
WO/2023/229295A1 |
The present invention relates to a phenylpropene derivative, and a pharmaceutical composition for the prevention or treatment of cancer, comprising the phenylpropene derivative as an active ingredient. The phenylpropene derivative disclo...
|
|
WO/2023/218970A1 |
Provided are, inter alia, an active-ray-sensitive or radiation-sensitive resin composition containing a resin that increases in polarity under the action of acid and a compound having a specified structure, an active-ray-sensitive or rad...
|
|
WO/2023/211103A1 |
The present invention provides: a fluorinated solvent having a specific structure; a non-aqueous electrolyte for a secondary battery, including a lithium salt and the fluorinated solvent; and a secondary battery including the non-aqueous...
|
|
WO/2023/209028A1 |
The invention relates to sulphonyl benzene derivatives, in particular to fluorinated sulphonyl benzene derivatives. It is provided a compound of formula (I) or general formula (IA) wherein X is fluorine; A is either O or NH; B is an amin...
|
|
WO/2023/179072A1 |
Disclosed in the present invention are a garlic antibacterial mixture as well as a preparation method therefor and the use thereof. The preparation method comprises the following preparation steps: taking a garlic extract as a raw materi...
|
|
WO/2023/172846A1 |
Provided are compounds of Formula (I):and pharmaceutically acceptable salts and compositions thereof, which are useful for treating a variety of conditions associated with PPARG.
|
|
WO/2023/151293A1 |
Disclosed in the present invention is a p-phenylcyclobutanamide rosemary compound and a preparation method therefor, and a use of the compound as a hyaluronidase inhibitor and an anti-aging beauty product. Specifically, disclosed in the ...
|
|
WO/2023/149556A1 |
The present disclosure provides a non-aqueous electrolyte containing at least one compound selected from the group consisting of (I) compounds represented by general formula (1) set forth in the specification and compounds represented by...
|
|
WO/2023/145804A1 |
The purpose of the present invention is to provide a novel B0AT1 inhibitor. The present invention relates to a compound represented by formula (I): (the symbols in the formula are as described in the description) or a salt thereof. The p...
|
|
WO/2023/146513A1 |
Provided herein are compounds and pharmaceutical compositions comprising said compounds that are useful for treating diseases. Specific diseases include those that are mediated by YAP/TAZ or those that are modulated by the interaction be...
|
|
WO/2023/137675A1 |
Disclosed in the present invention is the use of a nickel/ketone dual-catalysis system in a cross-coupling reaction of aryl halide and sodium arylsulfinate. Specifically, in a nitrogen atmosphere, aryl halide, sodium arylsulfinate, nicke...
|
|
WO/2023/127855A1 |
The present disclosure provides a novel synthetic intermediate of prostaglandin or an optically active substance thereof, and a production method that uses the same. More specifically, in the method according to the present disclosure fo...
|
|
WO/2023/127808A1 |
There is still a great amount of damage by pests or the like in production of agricultural crops, horticultural crops, and the like, and the development of novel pest control agents is desired due to factors such as the emergence of pest...
|
|
WO/2023/127807A1 |
In the production of agricultural and horticultural crops, etc., damages caused by pest insects, etc. are still significant, and, therefore, the development of novel pest control agents has been required due to factors such as the emerge...
|
|
WO/2023/122276A1 |
Provided herein are small molecule active metabotropic glutamate subtype-2 and -3 receptor positive allosteric modulators (PAMS), compositions comprising the compounds, and methods of using the compounds and compositions comprising the c...
|
|
WO/2023/090086A1 |
Provided are a secondary monohydrofluoroalkane selective adduct and a method for producing the same. A compound represented by formula (3) is produced by means of a method including a step for reacting a compound represented by formula (...
|
|
WO/2023/079111A1 |
The present invention relates to method for converting a sulfide of the following formula (I), such as yperite: R1-S-R2 (I) wherein R1 and R2, identical or different, are a (C1-C3)alkyl, (C2-C3)alkenyl, aryl, aryl- (C1-C3)alkyl, or aryl-...
|
|
WO/2023/074936A1 |
The present disclosure relates to a bifunctional compound using a UBR box domain-binding ligand. The UBR box domain is a domain commonly present in the UBR (Ubiquitin protein ligase E3 component n-recognin) protein of the N-end rule path...
|
|
WO/2023/077040A1 |
The disclosure relates to compounds of Formula (I), which are RXFP1 receptor agonists, compositions containing them, and methods of using them, for example, in the treatment of heart failure, fibrotic diseases, and related diseases such ...
|
|
WO/2023/065489A1 |
Provided are a high dielectric compound and a preparation method therefor, an epoxy high dielectric material and a preparation method therefor, and a semiconductor device. The high dielectric compound is represented by chemical formula (...
|
|
WO/2023/061464A1 |
Disclosed is a 2,3-dimethoxy-5-methyl-1,4-benzoquinone alkyl alcohol derivative, a pharmaceutical composition containing the compound, and the use of the compound in the prevention and treatment of tumors.
|
|
WO/2023/047104A9 |
The invention relates to a process for producing a compound comprising an 18F-difluoromethyl group or a compound comprising an 18F-difluoromethylene group, which process comprises contacting a compound comprising a nucleophilic group wit...
|
|
WO/2023/061999A1 |
The present invention discloses a distinct mode of action of a nickel catalyst to forge C-0 bonds to unlock the mild utilization of N2O as O-atom transfer reagent in the synthesis of complex phenols from the corresponding aryl halides.
|
|
WO/2023/043803A1 |
Disclosed herein are FABP4 and FABP5 inhibitor compounds and their use in pharmaceutical compositions for treating diseases relating to fatty acid metabolism, including cancer. Also disclosed herein are methods for preparing the disclose...
|
|
WO/2023/040105A1 |
Disclosed is a preparation method for a green visible light-catalyzed acetate compound. In this method, an LED lamp is used as a light source to provide energy, economically available primary, secondary, and tertiary alcohols are used as...
|
|
WO/2023/036868A1 |
The present invention relates to compounds of the formula (I) where X is selected from the group consisting of a single bond, O, N-(C1-C4)-alkyl, N-Ar1, CR5R6, S, S(O) and SO2; Z1 and Z2 are independently selected from hydrogen, -Alk-OH,...
|
|
WO/2023/038093A1 |
Provided is a deuterium-enriched composition comprising a deuterium-substituted carboxylic acid or a salt thereof, wherein the carboxylic acid or the salt thereof includes an α hydrogen of a carboxy group and a hydrogen other than the Î...
|
|
WO/2023/038156A1 |
The present invention relates to compounds of the formula (I) where X is selected from the group consisting of a single bond, O, N-(C1-C4)-alkyl, N-Ar1, CR5R6, S, S(O) and SO2; Z1 and Z2 are independently selected from hydrogen, -Alk-OH,...
|
|
WO/2023/018891A1 |
Disclosed herein is a method of treating a squamous cell carcinoma (SCC), a SCC associated with a disease, for example, recessive dystrophic epidermolysis bullosa (RDEB). The method of the disclosure describes administering a therapeutic...
|
|
WO/2023/003882A2 |
In one aspect, compounds and associated pharmaceutical compositions are described herein for the treatment of various fungal infections and/or other diseases. In some embodiments, for example, compounds of Formula (I) are described herein.
|
|
WO/2023/280773A1 |
The invention relates to chiral 3-sulfinyl benzoic acids of the absolute configuration specified in formulae (I-R) and (I-S) as precursors for the production of herbicidal compounds. In formulae (I-R) and (I-S), X, Z and R' represent gro...
|
|
WO/2022/270230A1 |
Provided is an active-light-sensitive or radiation-sensitive resin composition that yields a pattern having exceptional cross-sectional rectangularity. This active-light-sensitive or radiation-sensitive resin composition contains: a resi...
|
|
WO/2022/272288A1 |
Processes of producing nanoparticles from solid phase precursor non-nanoparticles. Contacting a solid phase precursor non-nanoparticle selected from oxides of metals and metalloids, carbides of metals and metalloids, nitrides of metals a...
|
|
WO/2022/266240A1 |
RAS proteins are frequently mutated in human cancers. Disclosed herein are compounds that disrupt RAS effectors and inhibits Ras/RafrMEK/ERK pathway signaling. Further disclosed herein are methods of using compounds in combination with c...
|
|
WO/2022/262597A1 |
The present invention provides a TNF-α small molecule inhibitor STU104, a preparation method therefor, and a use thereof. The absolute configuration of an optical isomer (R)-STU104 is identified, and in particular, it is found that STU1...
|
|
WO/2022/255770A1 |
The present invention relates to a novel squaramide derivative and a use thereof and provides a novel derivative through the strategy of replacing a compound having a urea core with the bioisolate squaramide, whereby the derivative exhib...
|
|
WO/2022/245991A1 |
Disclosed herein are novel uses of amisulpride derivatives and pharmaceutical compositions thereof, alone or in combination with other CNS active agents to antagonize dopamine and/or serotonin (e.g., 5-HT2a, 5-HT7) and/or alpha 2 recepto...
|
|
WO/2022/239798A1 |
A compound represented by formula (I) or a salt thereof. In formula (I), Ar represents a substituted or unsubstituted C6-C10 aryl group, etc.; L1 represents a single bond, etc.; L2 represents a single bond, etc.; X1 represents a cyano gr...
|
|
WO/2022/239534A1 |
[Abstract] [Problem] The purpose of the present invention is to provide novel meta-ester aromatic diamines, a method for producing the same, and polyimide synthesis. [Solution] Provided are compounds represented by formula (1). In formul...
|
|
WO/2022/226495A1 |
The present invention is directed to a method for treating spinal cord injury. The method comprises administering to a subject in need thereof 3-methanesulfonylpropionitrile (dapansutrile), or a pharmaceutically acceptable solvate thereo...
|
